Julio Aleman, PhD

CTO
Linton Lifesciences

As CTO of Linton Lifesciences, Julio Aleman brings a wealth of experience in bioengineering, bioprinting, and regenerative medicine. His extensive work includes serving as the scientific manager for the inaugural team at the RegenMed Development Organization (ReMDO) and as scientific lead of Microphysiological Systems at the Wake Forest Institute for Regenerative Medicine (WFIRM), where he developed multi-organ MPS platforms and led the development of universal bioinks for bioprinting various tissues. Julio's expertise was further honed at the Harvard-MIT Division of Health Sciences and Technology, where he contributed to escalating human-on-chip and bioprinting technology for drug discovery. He earned his PhD in Bioengineering at the University of Pittsburgh Swanson School of Engineering, leading an MPS Type 2 diabetes grant at the University of Pittsburgh Drug Discovery Institute (UPDDI) under Dr. Lans Taylor. His research encompasses tissue engineering, bioprinting, and sensor development, leading to numerous publications, recognition as an MIT Technology Review Innovator Under 35 LATAM, and a TEDx talk.

Disclosure information not submitted.

Presentation(s):

• Bioprinting of Patient-Specific Multiple Myeloma Models for Personalized Treatment

  Wednesday, April 15, 2026
  11:05 AM - 11:35 AM East Coast USA Time